Table 3. Clinical characteristics of the six subjects involved in serine supplementation study
Clinical variableBaseline (n = 6)After serine (n = 6)P‐value
Liver fat (%)26.8 ± 6.020.4 ± 7.0 <0.05
Age (years)56.7 ± 5.256.7 ± 5.2
Weight (kg)103.0 ± 14.3103.0 ± 13.9
Body mass index (BMI) (kg/m²)32.5 ± 2.7032.5 ± 2.60
Alanine aminotransferase (ALT) (U/l)50.8 ± 15.237.6 ± 5.3 <0.05
Aspartate aminotransferase (AST) (U/l)34.5 ± 8.1027.4 ± 8.4 <0.05
Alkaline phosphatase (ALP) (U/l)76.3 ± 17.271.3 ± 17.9 <0.05
γ‐glutamyl transferase (GT) (U/l)63.8 ± 12.962.3 ± 16.30.30
Fasting plasma glucose (mmol/l)6.57 ± 1.416.33 ± 1.410.25
Fasting plasma insulin (FPI) (pmol/l)46.3 ± 33.834.7 ± 25.20.23
HOMA‐IR2.15 ± 1.851.54 ± 1.490.18
LDL cholesterol (mmol/l)3.68 ± 0.803.85 ± 0.940.50
HDL cholesterol (mmol/l)1.00 ± 0.211.02 ± 0.180.30
Plasma triglycerides (TG) (mmol/l)6.90 ± 6.653.63 ± 1.810.13
Total cholesterol (mmol/l)6.23 ± 1.495.85 ± 1.150.18
Bilirubin (μmol/l)7.33 ± 4.116.48 ± 3.940.13
  • Data are presented as means ± SD. P‐value (calculated using Student's t‐test) indicates the significance level of difference before and after the oral supplementation of serine. Bold text indicate significantly different values.